OptiScan Biomedical Corporation, a Hayward, Calif.-based developer of an innovative continuous monitoring system for use in the surgical intensive care unit (SICU), closed a $20m Series E financing.
The company intends to use the funds for the commercialization of its lead product, the OptiScanner 5000, in the United States, and the expansion of the OptiScanner platform to monitor additional analytes of interest for critically ill patients.
Led by Cary G. Vance, chief executive officer, OptiScan has developed an innovative monitoring platform for use in hospital intensive care units (ICUs) to support clinicians in detecting changes rapidly in critically ill patients, enabling more timely intervention.
The OptiScanner® platform is presently focused on delivering automated bedside glucose monitoring to inform clinicians’ decision-making and maintain a user-defined target glucose range.
The company’s lead product, the OptiScanner 5000, is an automated, bedside glucose monitoring system that measures values directly from plasma using spectroscopy technology without the need for calibration.
The system displays trending glucose data with updates every 15 minutes to help manage patients’ glucose levels within an optimum target range.